Sidley advised Tricida, Inc. (Tricida; Nasdaq: TCDA) on a fast-moving registered direct equity financing. The financing includes the issuance of common stock and warrants at a premium to the previous market close. The funds raised will be used to extend Tricida’s financial runway and to continue to execute on their VALOR-CKD trial. Tricida is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Continue reading

See all Member News